<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116136">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093468</url>
  </required_header>
  <id_info>
    <org_study_id>MST-188-07</org_study_id>
    <nct_id>NCT02093468</nct_id>
  </id_info>
  <brief_title>Evaluation of MST-188 in Acute Lower Limb Ischemia</brief_title>
  <official_title>Evaluation of MST-188 in Acute Lower Limb Ischemia: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial Evaluating the Safety and Efficacy of MST-188 in Subjects With Acute Lower Limb Ischemia Receiving Catheter-Directed Recombinant Tissue Plasminogen Activator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate  the safety and efficacy of MST-188 in subjects
      receiving catheter-directed rt-PA for acute lower limb ischemia and to evaluate whether
      treatment with MST-188 results in more rapid thrombolysis of the occlusion and more rapid
      tissue perfusion in the effected blood vessel.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Angiographic assessment of the change in the volume of thrombus (Exploratory endpoint)</measure>
    <time_frame>Baseline, 8 and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the change in TcPO2 (Exploratory endpoint)</measure>
    <time_frame>Baseline, 8, 12, and 24  hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Randomization through 30 days post-treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline administered IV for 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MST-188</intervention_name>
    <arm_group_label>Lower Dose</arm_group_label>
    <arm_group_label>Higher Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥30 to  &lt;80

          -  Symptoms consistent with ALI in target lower limb classified as Rutherford Category
             IIa or IIb

          -  Subject is hospitalized or in the process of hospitalization for the treatment of ALI

          -  Angiographic confirmation of thrombotic lower limb arterial occlusion

        Exclusion Criteria:

          -  Prosthetic bypass graft occlusion within 1 month of implantation or autogenous graft
             occlusion within 6 months of placement

          -  Treatment with a thrombolytic agent within the last 48 hours

          -  Subject's laboratory results indicate inadequate organ function

          -  NYHA Class IV congestive heart failure

          -  Prior major amputation of the target limb

          -  Other complications or contraindications for receiving rt-PA, anticoagulants, or
             contrast media
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santosh Vetticaden, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mast Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mast Therapeutics CT.gov Call Center</last_name>
    <phone>1-888-965-1238</phone>
  </overall_contact>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute limb ischemia</keyword>
  <keyword>ALI</keyword>
  <keyword>Acute lower extremity arterial occlusion</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
